MedTech is one of the hardest B2B categories to commercialise. The global medical devices market is worth roughly US$720 billion in 2026 and heading toward US$1.2 trillion by 2035 (Precedence Research) — but individual product launches face 6–18 month buying cycles, purchasing committees of 5–12 stakeholders spanning clinical, technical, procurement, and administrative roles, and strict regulatory limits on what marketing can claim.
That combination — huge market, long cycles, committee buying, regulated claims — is precisely the environment where [account-based marketing](/account-based-marketing-strategy "ABM Strategy Guide") (ABM) outperforms volume demand generation. This guide explains what a MedTech GTM or ABM agency should actually do.
Why ABM fits MedTech
- The target universe is finite. There are only so many hospital systems, IDNs, clinics, and distributors in any territory. Broad-reach lead gen wastes budget on accounts that can never buy.
- Committees, not champions, buy. ITSMA research finds 87% of B2B marketers report higher ROI from ABM than any other approach — and the advantage grows when 5–12 stakeholders must align, because ABM engages the whole account rather than one form-filler.
- Buyers self-educate. [Gartner's B2B buying research](https://www.[gartner](https://www.gartner.com/en/sales/insights/b2b-buying-journey "Gartner B2B Buying Journey").com/en/sales/insights/b2b-buying-journey) shows buyers spend only ~17% of the journey with sales reps. In MedTech, clinicians research evidence independently — your clinical content, KOL voices, and account-level air cover do the early selling.
- Compliance survives account-level targeting. Company-level intent and engagement tracking avoids the person-level data problems that health-adjacent marketing runs into under GDPR/UK PECR and HIPAA-adjacent US rules.
What a MedTech GTM engagement should include
- Regulatory-aware messaging — claims mapped to your cleared/approved indications (510(k), CE mark, UKCA), reviewed against MDR/FDA advertising rules.
- Account universe build — a named list of target health systems, buying centres, and distributors, enriched with signals (tenders, formulary changes, leadership moves, funding).
- Clinical evidence content — white papers, health-economics one-pagers, and KOL-led material that committee members can circulate internally.
- Multi-channel ABM execution — LinkedIn to named accounts, intent monitoring, conference-synced outbound, and nurture built for 12-month cycles.
- Distributor/channel enablement — much of MedTech revenue flows through channel; your GTM system should arm it, not bypass it.
Choosing between a healthcare specialist and a GTM systems agency
Pure healthcare agencies bring regulatory fluency and clinical networks; GTM systems agencies bring modern data infrastructure (Clay, enrichment, intent) and ABM engineering. The best results usually come from pairing deep clinical review on your side with an agency that can actually build the account-based engine. Ask any candidate agency: who reviews claims, how they build the account universe, what signals they track, and what happens to the system when the engagement ends.
Related resources
- ABM Agency UK — the UK account-based marketing landscape
- Account-Based Marketing Strategy — the full ABM playbook
- Best GTM Agencies for Healthcare Tech
- Go-to-Market Strategy Agency — how GTM Quest builds 4-channel systems
- GTM Agency Directory
- Enterprise Sales Strategy — committee selling mechanics
FAQ
What does a MedTech ABM agency cost? UK programmes typically run £5K–£15K/month for a system-led ABM motion, more with paid media and conference support. US retainers trend higher. Given six-figure average deal values, one incremental health-system win usually pays for the year.
How long until ABM shows results in MedTech? Expect engagement signals (account coverage, committee reach) within a quarter, pipeline within two, and closed revenue on your normal 6–18 month cycle. Any agency promising closed MedTech deals in 90 days is guessing.
Can we market a device before clearance? You can build category awareness and scientific presence, but claims-based promotion must wait for clearance/approval in each market. A competent agency plans a pre-launch evidence phase and a post-clearance demand phase.
Does GTM Quest work with MedTech companies? Yes — we build compliant, account-based GTM systems for health tech and MedTech scale-ups entering UK and European markets. Book a strategy call.